The company focuses on leveraging the central role of probiotics and the gut microbiota on glycemic regulation in prediabetes, with the goal of providing long-term glycemic regulation. Genbioma develops food supplements and medicines that contain premium probiotics and other bioactive compounds, which are evidence-based and designed to spread the goodness of probiotics. Through its research and development platform, the company aims to help patients with early stages of diabetes achieve better health outcomes.